Skip to content

Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins

Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins The RELIEVE Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00565604
Acronym
RELIEVE
Enrollment
43
Registered
2007-11-30
Start date
2007-10-31
Completion date
2009-06-30
Last updated
2016-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Insufficiency

Keywords

Perforator Veins, Incompetent Veins, Varicose Veins

Brief summary

This trial is designed as a prospective, non randomized, single center clinical trial to determine the safety and efficacy of laser ablation of incompetent perforator veins. Within this clinical evaluation, fifty (50) limbs will be treated with Vari-Lase ®. A duplex ultrasound will verify the presence or absence of incompetent perforator veins (IPV). In addition, the number, diameter and location of the IPVs will be determined. Limbs with IPVs which measure greater than or equal to 3mm in diameter and are located superior to the foot and distal ankle will be considered for entry into the study.

Detailed description

This is a non randomized, single center clinical investigation, evaluating a total of fifty (50) limbs for the treatment of venous stasis ulcerations using the Vari-Lase laser. Subjects can be pre-screened utilizing standard of care data for the specified inclusion/exclusion criteria to ensure that they are eligible for treatment in the investigation. All subjects will have a mapping duplex ultrasound study in an Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) approved vascular laboratory. The ultrasound will verify the presence or absence of IPVs. The number, diameter, and location of the IPVs will be mapped. If the subject appears to qualify for the investigation, the subject will then be asked to give his/her written informed consent and be enrolled in the investigation. Upon satisfying all of the inclusion/exclusion criteria the subject will be accepted into the study. After enrollment, the investigator will document the CEAP class, venous clinical severity score (VCSS), and venous disability score (VDS) in the subject's chart/medical record/source documentation for later transcription on the appropriate case report form. Digital photographs will be taken of the limb to be treated prior to treatment with the subject standing, following a standardized photography regimen. All enrolled study participants will have a limb treated with the Vari-Lase laser manufactured by VSI. Subject preparation will be the same as for standard greater saphenous vein (GSV) or short saphenous vein, endovenous laser treatment. The initial technical success or failure of the procedure will be noted for each IPV and the pre-diameter of the IPV recorded. Multiple perforators may be treated in a single patient, as well as bilateral procedures allowed. Follow-up duplex exams will be conducted within the first week of treatment and at 6 months. Follow-up duplex will verify patency vs. closure of IPV, and presence or absence of deep vein thrombosis (DVT) associated with that IPV. The goal is to prove successful closure of the treated IPVs veins as demonstrated by the duplex ultrasound at 6 weeks and show maintained closure of IPVs at 6 months. Clinical examinations will occur at 2 weeks with an Associated Research Nurse Practitioner, at 6 weeks with the Medical Doctor, and at 6 months with either the Nurse Practitioner or Medical Doctor. At the 6 week visit, photos will be taken of the limb treated and there will be a reclassification of CEAP class, VDS, and VCSS.

Interventions

DEVICEShort Catheter Delivery

For treating incompetent perforator veins of the lower extremities

Sponsors

Vascular Solutions LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. The subject is 18 years of age or older. 2. The subject has the presence of incompetent perforator veins measuring \> 3 mm in diameter resultant of reflux documented on duplex ultrasound. 3. The subject has a CEAP classification of 3, 4, 5 or 6. 4. The subject has incompetent perforator veins that are superior to the foot and distal ankle. 5. The subject is willing and able to provide appropriate informed consent. 6. The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations.

Exclusion criteria

1. The subject has a history of significant arterial disease. 2. The subject is known to be, or suspected to be, pregnant (verified in a manner consistent with institution's standard of care), or is lactating. 3. The subject has an Ankle Brachial Index (ABI) of \< 0.5 4. The subject has occlusive thrombosis in the vein segment to be treated. 5. The subject has acute deep vein thrombosis. 6. The subject has an active or systemic infection. 7. The subject is or was enrolled in another investigational device or drug trial that may interfere with the results of this trial.

Design outcomes

Primary

MeasureTime frameDescription
Primary Effectiveness Objective6 MonthsThe primary objective is to demonstrate the clinical effectiveness (as determined by the absence of flow within the treated incompetent perforated vein \[IPV\])) of endovenous laser ablation. The number of treated IPVs that are closed at 6 weeks and remain closed at 6 months.
Primary Safety Objective6 MonthsSafety: Evaluation of occurrence of major device-related adverse events through 6 weeks and the total at 6 months.

Secondary

MeasureTime frameDescription
Secondary Effectiveness Objective6 MonthsEffectiveness: The reduction in patient symptoms and the satisfaction of the patient. Patient symptom assessment - CEAP Class, best=0 (no visible or palpable signs of venous disease) & worst=6 (Skin changes in conjunction with active ulceration), VDS, best=0 (asymptomatic) & worst=3 (unable to carry out usual activities even with compression and/or limb elevation) and VCSS, best=0 (absent) & worst=3 (severe). Patient satisfaction - modified Odom's criteria, best=excellent (I am very satisfied with the results of my laser treatment) & worst=poor (I am not satisfied with the results).
Secondary Safety Objective6 MonthsSafety: Incidence rate of device-related minor adverse events.

Countries

United States

Participant flow

Recruitment details

Subjects who had the presence of incompetent perforator veins were recruited from a medical clinic.

Pre-assignment details

Two subjects were withdrawn from the study immediately after the index procedure due to failure to treat any incompetent perforator veins.

Participants by arm

ArmCount
Short Catheter Delivery
Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
43
Total43

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyFailure to treat2
Overall StudyLost to Follow-up2

Baseline characteristics

CharacteristicShort Catheter Delivery
Age, Continuous54.1 years
STANDARD_DEVIATION 14.4
Region of Enrollment
United States
43 participants
Sex: Female, Male
Female
35 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
15 / 43
serious
Total, serious adverse events
0 / 43

Outcome results

Primary

Primary Effectiveness Objective

The primary objective is to demonstrate the clinical effectiveness (as determined by the absence of flow within the treated incompetent perforated vein \[IPV\])) of endovenous laser ablation. The number of treated IPVs that are closed at 6 weeks and remain closed at 6 months.

Time frame: 6 Months

Population: The number of patients still participating in the study at 6-months.

ArmMeasureGroupValue (NUMBER)
Short Catheter DeliveryPrimary Effectiveness ObjectiveIPV Closure-6 months53 Treated IPVs
Short Catheter DeliveryPrimary Effectiveness ObjectiveIPV Closure-6 weeks66 Treated IPVs
Primary

Primary Safety Objective

Safety: Evaluation of occurrence of major device-related adverse events through 6 weeks and the total at 6 months.

Time frame: 6 Months

Population: The number of patients that were enrolled in the study.

ArmMeasureGroupValue (NUMBER)
Short Catheter DeliveryPrimary Safety ObjectiveMajor Device-Related Adverse Events through 6 week14 Participants
Short Catheter DeliveryPrimary Safety ObjectiveMajor Device-Related Adverse Events Total 6 months15 Participants
Secondary

Secondary Effectiveness Objective

Effectiveness: The reduction in patient symptoms and the satisfaction of the patient. Patient symptom assessment - CEAP Class, best=0 (no visible or palpable signs of venous disease) & worst=6 (Skin changes in conjunction with active ulceration), VDS, best=0 (asymptomatic) & worst=3 (unable to carry out usual activities even with compression and/or limb elevation) and VCSS, best=0 (absent) & worst=3 (severe). Patient satisfaction - modified Odom's criteria, best=excellent (I am very satisfied with the results of my laser treatment) & worst=poor (I am not satisfied with the results).

Time frame: 6 Months

Population: The number of patients still participating in the study at 6-months.

ArmMeasureGroupValue (NUMBER)
Short Catheter DeliverySecondary Effectiveness ObjectiveVDS Improved30 Participants
Short Catheter DeliverySecondary Effectiveness ObjectivePatient Satisfaction (Good or Excellent)34 Participants
Short Catheter DeliverySecondary Effectiveness ObjectiveCEAP Class Improved29 Participants
Short Catheter DeliverySecondary Effectiveness ObjectiveVCSS Improved27 Participants
Secondary

Secondary Safety Objective

Safety: Incidence rate of device-related minor adverse events.

Time frame: 6 Months

Population: The number of subjects that were enrolled in the trial.

ArmMeasureValue (NUMBER)
Short Catheter DeliverySecondary Safety Objective5 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026